On November 2, 2020, the CHS held a live educational videoconference aimed to improve the understanding of FVIII/FIX inhibitors and treatment options, with a...
NOVEMBER 5-7 Many innovative and curative therapies are coming to market for rare blood disorders, but will they be available to Canadian patients? What is...
Access the most updated information regarding COVID-19 and inherited bleeding disorders: www.hemophilia.ca/covid-19
WFH Advisory: availability of desmopressin pending re-start of intranasal desmopressin manufacture
It is an exciting time in the treatment of people with bleeding disorders with many coagulation products having been recently approved by Health Canada or...
www.hemophilia.ca/coagulation-products
The World Federation of Hemophilia (WFH) has published the 3rd Edition of the Guidelines for the Management of Hemophilia, replacing the 2nd Edition published in...
In a decision that surprised many, the U.S. Food and Drug Administration (FDA) last week denied approval of Biomarin’s FVIII gene therapy, branded Roctavian. The...
Three decades of people with hemophilia unexposed to contaminated factor products and current treatments capable of suppressing and eliminating HIV and HCV, respectively, has again...
Hemlibra (emicizumab) is indicated in Canada for hemophilia A patients with or without factor VIII inhibitors as routine prophylaxis to prevent bleeding or reduce the...
The Plasma Protein Therapeutics Association (PPTA) represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the...
While preparing for the CHS’ national ageing retreat in 2018, Learning to learn and passing it on, we recognized that we had an opportunity...
While preparing for the CHS’ national ageing retreat in 2018, Learning to learn and passing it on, we recognized that we had an opportunity...
While preparing for the CHS’ national ageing retreat in 2018, Learning to learn and passing it on, we recognized that we had an opportunity...
